Glutathione/inosine - BAM
Alternative Names: BAM-205; Inosine glycyl-cysteinyl-glutamate disodium - Pharma VAM; Molixan; NOV-205Latest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator BAM
- Developer BAM; Cellectar Biosciences; North-Western State Medical University
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antivirals; Chemoprotectants; Hepatoprotectants; Oligopeptides; Purine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Immunomodulators; Nerve growth factor stimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B; Hepatitis C
- Phase III COVID 2019 infections
- Discontinued Radiation injuries
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Prevention) in Russia (Inhalation)
- 09 Mar 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in Russia (IM) (NCT04780672)
- 09 Mar 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in Russia (IV) (NCT04780672)